Skip to main content

Tybost FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved September 24, 2014)
Brand name: Tybost
Generic name: cobicistat
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection

Tybost (cobicistat) is a potent inhibitor of cytochrome P450 3A (CYP3A) which acts as a pharmacoenhancing or "boosting" agent for antiviral drugs used in the treatment of HIV infection.

Development timeline for Tybost

DateArticle
Sep 25, 2014Approval FDA Approves Tybost (cobicistat) for use in the treatment of HIV-1 Infection
Apr 21, 2014Gilead Sciences’ New Drug Application for Cobicistat for HIV Therapy Accepted by U.S. FDA
Apr 29, 2013Gilead Receives Complete Response Letters from U.S. Food and Drug Administration for Elvitegravir and Cobicistat
Jun 29, 2012Gilead Submits New Drug Application to U.S. FDA for Boosting Agent Cobicistat

See also

Tybost (cobicistat) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer